CAV1 and prostate carcinoma: The few patients (7%) with low tumor Cav-1 and high tumor PDGFRβ had an approximately 3-fold excess risk of prostate cancer death compared to the added separate relative risks for patients identified as having low tumor Cav-1, or high tumor PDGFRβ respectively (interaction analysis P <0.001) (Fig 4).